查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1223401

中東、非洲地區的乳癌診斷市場:產業趨勢、預測 (～2030年)

MEA Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 208 Pages | 商品交期: 請詢問到貨日

價格

中東、非洲地區的乳癌診斷的市場規模，從2022年～2029年的預測期間內預計以7.1％的年複合成長率成長。

女性及男性的乳癌患者增加，及乳癌診斷的技術進步高漲促進該市場的成長。

本報告提供中東、非洲地區的乳癌診斷的市場調查，市場概要，市場成長的各種影響因素分析，法律規範，市場規模的變化、預測，各種區分、各主要國家的明細，競爭環境，主要企業簡介等彙整資訊。

目錄

第1章 簡介

第2章 市場分類

第3章 摘要整理

第4章 重要考察

  • PESTEL分析
  • 波特的勢力分析

第5章 流行病學

第6章 產業的洞察

第7章 法律規範

第8章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第9章 中東、非洲地區的乳癌診斷市場:各檢驗類型

  • 概要
  • 成像
    • 電離乳房成像技術
    • 非電離成像技術
    • 切片檢查
    • 基因檢驗
  • 血液檢驗
  • 其他

第10章 中東、非洲地區的乳癌診斷市場:各類型

  • 概要
  • 浸潤性乳腺癌症
  • 表皮內乳腺癌症
  • 發炎性乳癌
  • 轉移性乳癌

第11章 中東、非洲地區的乳癌診斷市場:各終端用戶

  • 概要
  • 醫院
  • 診斷中心
  • 診所
  • 研究、學術機構
  • 其他

第12章 中東、非洲地區的乳癌診斷市場:各流通管道

  • 概要
  • 直接競標
  • 零售
  • 其他

第13章 中東、非洲地區的乳癌診斷市場:各地區

  • 中東、非洲
    • 埃及
    • 南非
    • 以色列
    • 沙烏地阿拉伯
    • UAE
    • 其他

第14章 中東、非洲地區的乳癌診斷市場:企業形勢

  • 企業佔有率分析:中東、非洲

第15章 SWOT分析

第16章 企業簡介

  • HOLOGIC, INC.
  • SIEMENS HEALTHCARE GMBH
  • F. HOFFMANN-LA ROCHE LTD
  • KONINKLIJKE PHILIPS N.V.
  • ABBOTT
  • ABACUS ALS
  • BD
  • BIOCEPT, INC.
  • BIOMERIEUX
  • BIO-RAD LABORATORIES, INC.
  • CEPHEID
  • EXACT SCIENCES CORPORATION
  • FUJIFILM CORPORATION
  • GENERAL ELECTRIC
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • NANOSTRING.
  • ONCOSTEM.
  • PROVISTA DIAGNOSTICS.
  • THERMO FISHER SCIENTIFIC INC.

第17章 問題事項

第18章 相關報告

Middle East and Africa breast cancer diagnostics market is projected to register a CAGR of 7.1% from 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East and Africa breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the Middle East and Africa breast cancer diagnostics market are:

Cepheid

BIOMERIEUX

Exact Sciences Corporation

Biocept, Inc.

Abacus ALS

TABLE OF CONTENTS

1 INTRODUCTION 48

  • 1.1 OBJECTIVES OF THE STUDY 48
  • 1.2 MARKET DEFINITION 48
  • 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET 48
  • 1.4 CURRENCY AND PRICING 50
  • 1.5 LIMITATIONS 50
  • 1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

  • 2.1 MARKETS COVERED 54
  • 2.2 GEOGRAPHICAL SCOPE 55
  • 2.3 YEARS CONSIDERED FOR THE STUDY 56
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
  • 2.6 MULTIVARIATE MODELLING 61
  • 2.7 MARKET END USER COVERAGE GRID 62
  • 2.8 TEST TYPE LIFELINE CURVE 63
  • 2.9 DBMR MARKET POSITION GRID 64
  • 2.10 VENDOR SHARE ANALYSIS 65
  • 2.11 SECONDARY SOURCES 66
  • 2.12 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

  • 4.1 PESTEL ANALYSIS 70
  • 4.2 PORTER'S 5 FORCES 71

5 EPIDEMIOLOGY 72

6 INDUSTRIAL INSIGHTS 73

7 REGULATORY FRAMEWORK 74

8 MARKET OVERVIEW 76

  • 8.1 DRIVERS 78
    • 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
    • 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
    • 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
    • 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
  • 8.2 RESTRAINTS 80
    • 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
    • 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
  • 8.3 OPPORTUNITIES 81
    • 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
    • 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
    • 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
  • 8.4 CHALLENGES 82
    • 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
    • 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83

9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84

  • 9.1 OVERVIEW 85
  • 9.2 IMAGING 88
    • 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
      • 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
      • 9.2.1.2 ANALOG MAMMOGRAPHY 90
      • 9.2.1.3 3D BREAST TOMOSYNTHESIS 90
      • 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
      • 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
      • 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
      • 9.2.1.7 OTHERS 90
    • 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
      • 9.2.2.1 OPTICAL IMAGING 91
      • 9.2.2.2 BREAST ULTRASOUND 91
      • 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
      • 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
      • 9.2.2.5 BREAST THERMOGRAPHY 92
    • 9.2.3 BIOPSY 92
      • 9.2.3.1 SURGICAL BIOPSY 93
      • 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
      • 9.2.3.3 CORE NEEDLE BIOPSY 93
      • 9.2.3.4 IMAGE-GUIDED BIOPSY 93
      • 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
    • 9.2.4 GENOMIC TEST 94
      • 9.2.4.1 MOLECULAR TESTING 95
        • 9.2.4.1.1 PD-L1 96
        • 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
        • 9.2.4.1.3 NTRK GENE FUSIONS 96
        • 9.2.4.1.4 PI3KCA GENE MUTATION 96
      • 9.2.4.2 MAMMAPRINT 96
      • 9.2.4.3 ONCOTYPE DX 96
      • 9.2.4.4 OTHERS 96
  • 9.3 BLOOD TEST 97
  • 9.4 OTHERS 98

10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99

  • 10.1 OVERVIEW 100
  • 10.2 INVASIVE DUCTAL CARCINOMA 103
  • 10.3 DUCTAL CARCINOMA IN SITU 103
  • 10.4 INFLAMMATORY BREAST CANCER 104
  • 10.5 METASTATIC BREAST CANCER 105

11 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106

  • 11.1 OVERVIEW 107
  • 11.2 HOSPITALS 109
  • 11.3 DIAGNOSTICS CENTERS 110
  • 11.4 CLINICS 111
  • 11.5 RESEARCH & ACADEMIC INSTITUTES 111
  • 11.6 OTHERS 112

12 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114

  • 12.1 OVERVIEW 115
  • 12.2 DIRECT TENDER 118
  • 12.3 RETAIL SALES 118
  • 12.4 OTHERS 119

13 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120

  • 13.1 MIDDLE EAST AND AFRICA 121
    • 13.1.1 EGYPT 130
    • 13.1.2 SOUTH AFRICA 136
    • 13.1.3 ISRAEL 142
    • 13.1.4 SAUDI ARABIA 148
    • 13.1.5 UAE 154
    • 13.1.6 REST OF MIDDLE EAST AND AFRICA 160

14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 161

  • 14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 161

15 SWOT ANALYSIS 162

16 COMPANY PROFILE 163

  • 16.1 HOLOGIC, INC. 163
    • 16.1.1 COMPANY SNAPSHOT 163
    • 16.1.2 REVENUE ANALYSIS 163
    • 16.1.3 COMPANY SHARE ANALYSIS 164
    • 16.1.4 PRODUCT PORTFOLIO 164
    • 16.1.5 RECENT DEVELOPMENTS 165
  • 16.2 SIEMENS HEALTHCARE GMBH 166
    • 16.2.1 COMPANY SNAPSHOT 166
    • 16.2.2 REVENUE ANALYSIS 167
    • 16.2.3 COMPANY SHARE ANALYSIS 167
    • 16.2.4 PRODUCT PORTFOLIO 168
    • 16.2.5 RECENT DEVELOPMENTS 168
  • 16.3 F. HOFFMANN- LA ROCHE LTD 169
    • 16.3.1 COMPANY SNAPSHOT 169
    • 16.3.2 REVENUE ANALYSIS 169
    • 16.3.3 COMPANY SHARE ANALYSIS 170
    • 16.3.4 PRODUCT PORTFOLIO 170
    • 16.3.5 RECENT DEVELOPMENTS 171
  • 16.4 KONINKLIJKE PHILIPS N.V. 172
    • 16.4.1 COMPANY SNAPSHOT 172
    • 16.4.2 REVENUE ANALYSIS 172
    • 16.4.3 COMPANY SHARE ANALYSIS 173
    • 16.4.4 PRODUCT PORTFOLIO 173
    • 16.4.5 RECENT DEVELOPMENTS 174
  • 16.5 ABBOTT 175
    • 16.5.1 COMPANY SNAPSHOT 175
    • 16.5.2 REVENUE ANALYSIS 175
    • 16.5.3 COMPANY SHARE ANALYSIS 176
    • 16.5.4 PRODUCT PORTFOLIO 176
    • 16.5.5 RECENT DEVELOPMENTS 176
  • 16.6 ABACUS ALS 177
    • 16.6.1 COMPANY SNAPSHOT 177
    • 16.6.2 PRODUCT PORTFOLIO 177
    • 16.6.3 RECENT DEVELOPMENTS 177
  • 16.7 BD 178
    • 16.7.1 COMPANY SNAPSHOT 178
    • 16.7.2 REVENUE ANALYSIS 178
    • 16.7.3 COMPANY SHARE ANALYSIS 179
    • 16.7.4 PRODUCT PORTFOLIO 179
    • 16.7.5 RECENT DEVELOPMENTS 179
  • 16.8 BIOCEPT, INC. 180
    • 16.8.1 COMPANY SNAPSHOT 180
    • 16.8.2 REVENUE ANALYSIS 180
    • 16.8.3 PRODUCT PORTFOLIO 181
    • 16.8.4 RECENT DEVELOPMENTS 181
  • 16.9 BIOMERIEUX 182
    • 16.9.1 COMPANY SNAPSHOT 182
    • 16.9.2 REVENUE ANALYSIS 182
    • 16.9.3 PRODUCT PORTFOLIO 183
    • 16.9.4 RECENT DEVELOPMENTS 183
  • 16.10 BIO-RAD LABORATORIES, INC. 184
    • 16.10.1 COMPANY SNAPSHOT 184
    • 16.10.2 REVENUE ANALYSIS 184
    • 16.10.3 PRODUCT PORTFOLIO 185
    • 16.10.4 RECENT DEVELOPMENT 185
  • 16.11 CEPHEID 186
    • 16.11.1 COMPANY SNAPSHOT 186
    • 16.11.2 REVENUE ANALYSIS 186
    • 16.11.3 PRODUCT PORTFOLIO 187
    • 16.11.4 RECENT DEVELOPMENT 187
  • 16.12 EXACT SCIENCES CORPORATION 188
    • 16.12.1 COMPANY SNAPSHOT 188
    • 16.12.2 REVENUE ANALYSIS 188
    • 16.12.3 COMPANY SHARE ANALYSIS 189
    • 16.12.4 PRODUCT PORTFOLIO 189
    • 16.12.5 RECENT DEVELOPMENTS 190
  • 16.13 FUJIFILM CORPORATION 191
    • 16.13.1 COMPANY SNAPSHOT 191
    • 16.13.2 REVENUE ANALYSIS 191
    • 16.13.3 PRODUCT PORTFOLIO 192
    • 16.13.4 RECENT DEVELOPMENT 192
  • 16.14 GENERAL ELECTRIC 193
    • 16.14.1 COMPANY SNAPSHOT 193
    • 16.14.2 REVENUE ANALYSIS 193
    • 16.14.3 PRODUCT PORTFOLIO 194
    • 16.14.4 RECENT DEVELOPMENTS 194
  • 16.15 ILLUMINA, INC. 195
    • 16.15.1 COMPANY SNAPSHOT 195
    • 16.15.2 REVENUE ANALYSIS 195
    • 16.15.3 PRODUCT PORTFOLIO 196
    • 16.15.4 RECENT DEVELOPMENTS 196
  • 16.16 MYRIAD GENETICS, INC. 197
    • 16.16.1 COMPANY SNAPSHOT 197
    • 16.16.2 REVENUE ANALYSIS 197
    • 16.16.3 PRODUCT PORTFOLIO 198
    • 16.16.4 RECENT DEVELOPMENT 198
  • 16.17 NANOSTRING. 199
    • 16.17.1 COMPANY SNAPSHOT 199
    • 16.17.2 REVENUE ANALYSIS 199
    • 16.17.3 PRODUCT PORTFOLIO 200
    • 16.17.4 RECENT DEVELOPMENT 200
    • 16.17.5 RECENT DEVELOPMENT 200
  • 16.18 ONCOSTEM. 201
    • 16.18.1 COMPANY SNAPSHOT 201
    • 16.18.2 PRODUCT PORTFOLIO 201
    • 16.18.3 RECENT DEVELOPMENT 201
  • 16.19 PROVISTA DIAGNOSTICS. 202
    • 16.19.1 COMPANY SNAPSHOT 202
    • 16.19.2 PRODUCT PORTFOLIO 202
    • 16.19.3 RECENT DEVELOPMENT 202
  • 16.20 THERMO FISHER SCIENTIFIC INC. 203
    • 16.20.1 COMPANY SNAPSHOT 203
    • 16.20.2 REVENUE ANALYSIS 203
    • 16.20.3 PRODUCT PORTFOLIO 204
    • 16.20.4 RECENT DEVELOPMENT 204

17 QUESTIONNAIRE 205

18 RELATED REPORTS 208

LIST OF TABLES

  • TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 44
  • TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 44
  • TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 44
  • TABLE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 59
  • TABLE 5 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 60
  • TABLE 6 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 60
  • TABLE 7 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 61
  • TABLE 8 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 61
  • TABLE 9 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 63
  • TABLE 10 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 63
  • TABLE 11 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
  • TABLE 12 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 13 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 65
  • TABLE 14 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 66
  • TABLE 15 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
  • TABLE 16 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 67
  • TABLE 17 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
  • TABLE 18 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 68
  • TABLE 19 MIDDLE EAST & AFRICA BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
  • TABLE 20 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
  • TABLE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 74
  • TABLE 22 MIDDLE EAST & AFRICA INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
  • TABLE 23 MIDDLE EAST & AFRICA DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
  • TABLE 24 MIDDLE EAST & AFRICA INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 25 MIDDLE EAST & AFRICA METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 81
  • TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 28 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 29 MIDDLE EAST & AFRICA CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 30 MIDDLE EAST & AFRICA RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 31 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
  • TABLE 32 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 89
  • TABLE 33 MIDDLE EAST & AFRICA DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 34 MIDDLE EAST & AFRICA RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 35 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 36 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 97
  • TABLE 37 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 38 MIDDLE EAST AND AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 39 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 40 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 98
  • TABLE 41 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 42 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 99
  • TABLE 43 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 44 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 99
  • TABLE 45 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 46 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 100
  • TABLE 47 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 48 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 100
  • TABLE 49 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 50 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 101
  • TABLE 51 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 101
  • TABLE 52 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 53 EGYPT IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 54 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 55 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 103
  • TABLE 56 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 103
  • TABLE 57 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 58 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 104
  • TABLE 59 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
  • TABLE 60 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 61 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 104
  • TABLE 62 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
  • TABLE 63 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 64 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 105
  • TABLE 65 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
  • TABLE 66 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 67 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 106
  • TABLE 68 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 106
  • TABLE 69 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 70 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
  • TABLE 71 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 107
  • TABLE 72 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 73 SOUTH AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 74 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 75 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
  • TABLE 76 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 109
  • TABLE 77 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 78 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
  • TABLE 79 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
  • TABLE 80 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 81 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
  • TABLE 82 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
  • TABLE 83 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 84 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 111
  • TABLE 85 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
  • TABLE 86 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 87 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 112
  • TABLE 88 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 112
  • TABLE 89 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 90 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
  • TABLE 91 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 113
  • TABLE 92 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 93 ISRAEL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 94 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 95 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
  • TABLE 96 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 115
  • TABLE 97 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 98 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
  • TABLE 99 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
  • TABLE 100 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 101 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
  • TABLE 102 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
  • TABLE 103 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 104 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 117
  • TABLE 105 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
  • TABLE 106 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 107 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 118
  • TABLE 108 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 118
  • TABLE 109 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 110 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 118
  • TABLE 111 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
  • TABLE 112 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 113 SAUDI ARABIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 114 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 115 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
  • TABLE 116 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 121
  • TABLE 117 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 118 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
  • TABLE 119 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
  • TABLE 120 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 121 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
  • TABLE 122 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
  • TABLE 123 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 124 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 123
  • TABLE 125 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
  • TABLE 126 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 127 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 124
  • TABLE 128 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 124
  • TABLE 129 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 130 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 124
  • TABLE 131 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 125
  • TABLE 132 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 133 UAE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 134 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 135 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
  • TABLE 136 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 127
  • TABLE 137 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 138 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
  • TABLE 139 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
  • TABLE 140 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 141 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
  • TABLE 142 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
  • TABLE 143 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 144 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 129
  • TABLE 145 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
  • TABLE 146 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 147 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 130
  • TABLE 148 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 130
  • TABLE 149 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 150 UAE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
  • TABLE 151 UAE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
  • TABLE 152 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 25
  • FIGURE 2 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 28
  • FIGURE 3 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 29
  • FIGURE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 30
  • FIGURE 5 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 30
  • FIGURE 6 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 31
  • FIGURE 7 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 33
  • FIGURE 8 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 35
  • FIGURE 9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 36
  • FIGURE 10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 39
  • FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 40
  • FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 40
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET 48
  • FIGURE 14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 56
  • FIGURE 15 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 57
  • FIGURE 16 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 57
  • FIGURE 17 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 58
  • FIGURE 18 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 71
  • FIGURE 19 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 72
  • FIGURE 20 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 72
  • FIGURE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 73
  • FIGURE 22 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 78
  • FIGURE 23 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 79
  • FIGURE 24 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 79
  • FIGURE 25 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 80
  • FIGURE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 86
  • FIGURE 27 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 87
  • FIGURE 28 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 87
  • FIGURE 29 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 88
  • FIGURE 30 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 93
  • FIGURE 31 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 94
  • FIGURE 32 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 94
  • FIGURE 33 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 95
  • FIGURE 34 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 95
  • FIGURE 35 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 132